Trial reportAbdominal radiology (New York)2020
Observer agreement for small bowel ultrasound in Crohn's disease: results from the METRIC trial.
Trial report in Abdominal radiology (New York), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Bowel Wall Vascularization in Crohn's Disease: Exploratory Comparison of Vendor-Derived Vascular Index, ImageJ-Based Quantification, and Blinded Video-Based Doppler Scoring.Diagnostics (Basel, Switzerland) · 2026Article
- Development and validation of a novel intestinal ultrasound score for predicting endoscopic activity of ileocecal ulcers in intestinal Behçet's disease.Journal of gastroenterology · 2026Article
- Magnetic Resonance Enterography and Intestinal Ultrasound for the Assessment and Monitoring of Crohn's Disease.Journal of Crohn's & colitis · 2024Review
- Role of Intestinal Ultrasound for IBD Care: A Practical Approach.Diagnostics (Basel, Switzerland) · 2024Review
- Intestinal ultrasound for intestinal Behçet disease reflects endoscopic activity and histopathological findings.Intestinal research · 2024Article
- Current and Novel Uses of Intestinal Ultrasound in Inflammatory Bowel Disease.Gastroenterology & hepatology · 2023Article
- Article
- Intestinal ultrasound as a non-invasive tool to monitor inflammatory bowel disease activity and guide clinical decision making.World journal of gastroenterology · 2023Review
- The Family Level Assessment of Screen Use-Mobile Approach: Development of an Approach to Measure Children's Mobile Device Use.JMIR formative research · 2022Article
- Treat to transmural healing: how to incorporate intestinal ultrasound into the treatment of inflammatory bowel disease.The British journal of radiology · 2022Review
- Imaging in inflammatory bowel disease: current and future perspectives.Frontline gastroenterology · 2022Article
- Ultrasound use to assess Crohn's disease in the UK: a survey of British Society of Gastroenterology Inflammatory Bowel Disease Group members.Frontline gastroenterology · 2022Article
- Clinical utility of small bowel ultrasound assessment of Crohn's disease in adults: a systematic scoping review.Frontline gastroenterology · 2022Article
- Impact of intestinal ultrasound with a portable system in the management of Crohn's disease.Gastroenterology report · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo prospectively evaluate interobserver agreement for small bowel ultrasound (SBUS) in newly diagnosed and relapsing Crohn's disease.
methodsA subset of patients recruited to a prospective trial comparing the diagnostic accuracy of MR enterography and SBUS underwent a second SBUS performed by one of a pool of six practitioners, who recorded the presence, activity and location of small bowel and colonic disease. Detailed segmental mural and extra-mural observations were also scored. Interobserver variability was expressed as percentage agreement with a construct reference standard, split by patient cohort, grouping disease as present or absent. Prevalence adjusted bias adjusted kappa (PABAK), and simple percentage agreement between practitioners, irrespective of the reference standard, were calculated.
resultsThirty-eight patients (11 new diagnosis, 27 relapse) were recruited from two sites. Overall percentage agreement for small bowel disease presence against the consensus reference was 82% (52-95% (95%CI)), kappa coefficient (κ) 0.64, (substantial agreement) for new diagnosis and 81%, κ 0.63 (substantial agreement) for the relapsing cohort. Agreement for colonic disease presence was 64%, κ 0.27 (fair agreement) in new diagnosis and 78%,κ 0.56 (moderate agreement) in the relapsing cohort. Simple agreement between practitioners was 84% and 87% for small bowel and colonic disease presence respectively. Practitioners agreed on small bowel disease activity in 24/27 (89%) where both identified disease. Kappa agreement for detailed mural observations ranged from κ 0.00 to 1.00.
conclusionThere is substantial practitioner agreement for small bowel disease presence in newly diagnosed and relapsing CD patients, supporting wider dissemination of enteric US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.